We are live on ! Find out more
FTH

Faeth Therapeutics

40 hedge funds and large institutions have $45.7M invested in Faeth Therapeutics in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.52% more ownership

Funds ownership: 0%0.52% (+0.52%)

Holders
40
Holders Change
+40
Holders Change %
% of All Funds
0.7%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
40
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Sellers

No sellers this quarter

FTH Hedge Fund Activity: Q1 2021 in Review

40 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2021, worth a combined $45.7M.

Buyers outnumbered sellers: 40 funds opened new FTH positions and 0 closed out — a net gain of 40 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $11.6M.

  • 40 institutional investors held Faeth Therapeutics (FTH) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $45.7M of Faeth Therapeutics stock for Q1 2021.
  • 40 funds opened new Faeth Therapeutics positions in Q1 2021 and 0 closed out, a net change of +40 holders.
  • The largest Faeth Therapeutics buyer in Q1 2021 was Citadel Advisors, an estimated $11.6M added.

Based on aggregated 13F filings for Q1 2021.